FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...
Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...
*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback